# Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection

> **NCT03794258** · PHASE2 · WITHDRAWN · sponsor: **Humanity & Health Medical Group Limited**

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** SOF+DCV+CDI-31244
- **DRUG:** SOF+DCV+CDI-31244+ASV

## Key facts

- **NCT ID:** NCT03794258
- **Lead sponsor:** Humanity & Health Medical Group Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05-01
- **Primary completion:** 2020-04-15
- **Final completion:** 2020-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Can not recruit the patients due to the pandemic of COVID-19
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794258, "Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03794258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*